Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cardiol Therapeutics Inc T.CRDL

Alternate Symbol(s):  CRDL

Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.


TSX:CRDL - Post by User

Comment by NewFanCBDon Jun 29, 2020 9:00am
138 Views
Post# 31202077

RE:Grasso as advisor

RE:Grasso as advisor

This is a big deal! Having Grasso on board with his 68,000 Twitter followers, is awesome. He sees huge potential in the marijuana sector, but I am sure he will be especially intrigued by Cardiol, it's pure Cannabidiol  platform and the therapeutic values associated to it, the purity of it, and especially related to potential COVID-19 therapies.

I see the share price here getting a huge boost here over the next couple of months with Steve Grasso on board now with Cardiol. Glad I purchased here in the $2.40 level to average down.  If you're short, you're going to be in deep S#\T. It's the synergies that 'Steve brings to the table here that could really make this stock sing.

Love it!!! 

<< Previous
Bullboard Posts
Next >>